» Articles » PMID: 38889004

Insights on Epidemiology, Morbidity and Mortality of Cushing's Disease in Northern Ireland

Abstract

Cushing's disease is a rare condition that occurs due to an adrenocorticotrophin-producing corticotrophinoma arising from the pituitary gland. The consequent hypercortisolaemia results in multisystem morbidity and mortality. This study aims to report incidence, clinicopathological characteristics, remission outcomes and mortality in a regional pituitary neurosurgical cohort of patients diagnosed with Cushing's disease in Northern Ireland (NI) from 2000 to 2019. Clinical, biochemical and radiological data from a cohort of patients operated for Cushing's disease were retrospectively collected and analysed. Fifty-three patients were identified, resulting in an estimated annual incidence of Cushing's disease of 1.39-1.57 per million population per year. Females accounted for 72% (38/53) of the cohort. The majority (74%, 39/53) of corticotrophinomas were microadenomas and in 44% (17/39) of these no tumour was identified on preoperative magnetic resonance imaging. Histopathological characterisation was similarly difficult, with no tumour being identified in the histopathological specimen in 40% (21/53) of cases. Immediate postoperative remission rates were 53% and 66% when considering serum morning cortisol cut-offs of ≤ 50 nmol/L (1.8 µg/dL) and ≤ 138 nmol/L (5 µg/dL), respectively, in the week following pituitary surgery. Approximately 70% (37/53) of patients achieved longer-term remission with a single pituitary surgery. Three patients had recurrent disease. Patients with Cushing's disease had a significantly higher mortality rate compared to the NI general population (standardised mortality ratio 8.10, 95% CI 3.3-16.7, P < 0.001). Annual incidence of Cushing's disease in NI is consistent with other Northern European cohorts. Functioning corticotrophinomas are a clinically, radiologically and histopathologically elusive disease with increased mortality compared to the general population.

Citing Articles

Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studies.

Fleseriu M, Pivonello R, Newell-Price J, Gadelha M, Biller B, Auchus R Pituitary. 2025; 28(1):22.

PMID: 39863744 PMC: 11762609. DOI: 10.1007/s11102-024-01471-3.

References
1.
Alexandraki K, Kaltsas G, Isidori A, Storr H, Afshar F, Sabin I . Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. Eur J Endocrinol. 2013; 168(4):639-48. DOI: 10.1530/EJE-12-0921. View

2.
PLOTZ C, KNOWLTON A, RAGAN C . The natural history of Cushing's syndrome. Am J Med. 1952; 13(5):597-614. DOI: 10.1016/0002-9343(52)90027-2. View

3.
Saini S, Kanwar J, Gupta S, Behari S, Bhatia E, Yadav S . Long-term outcome of trans-sphenoidal surgery for Cushing's disease in Indian patients. Acta Neurochir (Wien). 2018; 161(1):119-127. DOI: 10.1007/s00701-018-3736-0. View

4.
Mondin A, Ceccato F, Voltan G, Mazzeo P, Manara R, Denaro L . Complications and mortality of Cushing's disease: report on data collected over a 20-year period at a referral centre. Pituitary. 2023; 26(5):551-560. PMC: 10539191. DOI: 10.1007/s11102-023-01343-2. View

5.
Nieman L, Biller B, Findling J, Murad M, Newell-Price J, Savage M . Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(8):2807-31. PMC: 4525003. DOI: 10.1210/jc.2015-1818. View